Vanguard Group Inc. Boosts Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Vanguard Group Inc. increased its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 4.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 6,437,155 shares of the company's stock after buying an additional 250,812 shares during the period. Vanguard Group Inc. owned about 5.53% of MiMedx Group worth $46,927,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. BlackRock Inc. raised its position in shares of MiMedx Group by 2.0% during the second quarter. BlackRock Inc. now owns 8,118,485 shares of the company's stock valued at $53,663,000 after buying an additional 160,933 shares during the last quarter. State Street Corp grew its stake in MiMedx Group by 6.0% during the first quarter. State Street Corp now owns 4,406,544 shares of the company's stock valued at $20,755,000 after acquiring an additional 250,334 shares in the last quarter. Geode Capital Management LLC increased its holdings in MiMedx Group by 6.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,331,277 shares of the company's stock valued at $15,410,000 after acquiring an additional 132,740 shares during the last quarter. Cannell Capital LLC lifted its stake in MiMedx Group by 106.7% in the 3rd quarter. Cannell Capital LLC now owns 2,273,762 shares of the company's stock worth $16,576,000 after purchasing an additional 1,173,506 shares in the last quarter. Finally, Federated Hermes Inc. boosted its holdings in shares of MiMedx Group by 2,943.6% during the 1st quarter. Federated Hermes Inc. now owns 1,718,749 shares of the company's stock valued at $8,095,000 after purchasing an additional 1,662,278 shares during the last quarter. Hedge funds and other institutional investors own 79.15% of the company's stock.

MiMedx Group Trading Down 6.7 %

Shares of NASDAQ:MDXG traded down $0.47 during trading on Wednesday, reaching $6.55. The company's stock had a trading volume of 1,132,250 shares, compared to its average volume of 776,108. The firm's 50 day simple moving average is $7.87 and its two-hundred day simple moving average is $7.66. The company has a current ratio of 3.57, a quick ratio of 3.11 and a debt-to-equity ratio of 0.34. MiMedx Group, Inc. has a 12 month low of $3.13 and a 12 month high of $9.27. The stock has a market capitalization of $962.59 million, a PE ratio of 20.63 and a beta of 1.32.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). The company had revenue of $86.83 million during the quarter, compared to the consensus estimate of $85.58 million. MiMedx Group had a net margin of 14.49% and a return on equity of 41.12%. On average, research analysts predict that MiMedx Group, Inc. will post 0.33 EPS for the current fiscal year.

Analyst Ratings Changes

MDXG has been the topic of several research reports. Mizuho lifted their target price on MiMedx Group from $13.00 to $14.00 and gave the stock a "buy" rating in a report on Friday, March 1st. Lake Street Capital started coverage on MiMedx Group in a research note on Thursday, March 7th. They issued a "buy" rating and a $12.00 price objective on the stock. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $12.25.

Insider Buying and Selling at MiMedx Group

In other MiMedx Group news, COO Ricci S. Whitlow sold 15,271 shares of the firm's stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $8.01, for a total value of $122,320.71. Following the completion of the sale, the chief operating officer now owns 401,050 shares of the company's stock, valued at $3,212,410.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other MiMedx Group news, COO Ricci S. Whitlow sold 15,271 shares of the company's stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $8.01, for a total value of $122,320.71. Following the transaction, the chief operating officer now owns 401,050 shares of the company's stock, valued at approximately $3,212,410.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Ricci S. Whitlow sold 15,493 shares of MiMedx Group stock in a transaction on Friday, February 16th. The stock was sold at an average price of $8.07, for a total value of $125,028.51. Following the sale, the chief operating officer now owns 416,321 shares of the company's stock, valued at $3,359,710.47. The disclosure for this sale can be found here. Insiders have sold 51,145 shares of company stock worth $409,378 over the last quarter. Insiders own 19.90% of the company's stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.